Thalidomide administration inhibits the clinical evolution of the experimental autoimmune encephalomyelitis (eae) in lewis rats: preliminar results
Rev. interdisciplin. estud. exp. anim. hum. (impr.)
;
1(2): 58-61, Junho 2009. tab
Article
in English
| LILACS
| ID: biblio-964323
ABSTRACT
Multiple sclerosis (MS) is a chronic neurodegenerative inflammatory disease of the central nervous system. Several immunomodulatory agents have been used to prevent MS acute exacerbations. Tumor Necrosis factor alpha (TNFα) and interferon gamma (IFN-γ) are two major inflammatory mediators. Recently, we investigated in our laboratory the therapeutic value of thalidomide, a recognized TNF-α inhibitor, for the treatment of MS using the classical Lewis rat model of experimental autoimmune encephalomyelitis ( EAE). The experimental study revealed that thalidomide reduces the incidence of EAE development in 90% of the cases. Hence we hypothesized that thalidomide may be an important therapeutical tool for prevention of acute exacerbations of the MS.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Thalidomide
/
Multiple Sclerosis, Relapsing-Remitting
/
Encephalomyelitis, Autoimmune, Experimental
Type of study:
Prognostic study
Limits:
Animals
Language:
English
Journal:
Rev. interdisciplin. estud. exp. anim. hum. (impr.)
Journal subject:
Biology
Year:
2009
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Laboratory Analisys/BR
Similar
MEDLINE
...
LILACS
LIS